España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Genmab
GMAB
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$20.14
0.11
0.55%
At close: -
$20.10
-0.04
-0.20%
After Hours: 4:24 PM EDT
Get Report
Comment
Genmab (GMAB) Forecast
News
Earnings
Genmab (GMAB) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Genmab (NASDAQ:GMAB) Stock
Genmab Stock (NASDAQ: GMAB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 09, 2024
AbbVie And Genmab A/S Present Two Data Analys...
Benzinga Newsdesk
Reported Sunday, Genmab Presents Phase 1b/2 D...
Benzinga Newsdesk
Sunday, December 08, 2024
Genmab Announced Investigational Epcoritamab ...
Benzinga Newsdesk
Friday, November 08, 2024
A Closer Look at 10 Analyst Recommendations For Genmab
Benzinga Insights
BMO Capital Reiterates Outperform on Genmab, ...
Benzinga Newsdesk
Wednesday, November 06, 2024
Genmab Reports 29% Revenue Growth For First N...
Benzinga Newsdesk
Tuesday, November 05, 2024
Genmab To Showcase Strength And Breadth Of Co...
Benzinga Newsdesk
Preview: Genmab's Earnings
Benzinga Insights
Tuesday, October 29, 2024
Revitope Oncology Signs License Agreement Pro...
Benzinga Newsdesk
Wednesday, October 16, 2024
12 Analysts Have This To Say About Genmab
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Tuesday, October 15, 2024
Genmab Reports $3B in DARZALEX Sales for Q3 2...
Benzinga Newsdesk
Tuesday, October 08, 2024
Down -14.68% in 4 Weeks, Here's Why Genmab Looks Ripe for a Turnaround
Zacks
Friday, October 04, 2024
Genmab A/S Says Baillie Gifford & Co Held The...
Benzinga Newsdesk
Monday, September 23, 2024
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
Friday, September 20, 2024
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Monday, September 16, 2024
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Reported Sunday, Genmab's Rinatabart Sesuteca...
Benzinga Newsdesk
Friday, September 13, 2024
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Wednesday, September 11, 2024
Morgan Stanley Maintains Equal-Weight on Genm...
Benzinga Newsdesk
Monday, September 09, 2024
Expert Ratings For Genmab
Benzinga Insights
Truist Securities Maintains Buy on Genmab, Lo...
Benzinga Newsdesk
Wednesday, September 04, 2024
Morgan Stanley Reinstates Equal-Weight on Gen...
Benzinga Newsdesk
Tuesday, August 27, 2024
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Tuesday, August 20, 2024
Decoding 10 Analyst Evaluations For Genmab
Benzinga Insights
Genmab shares are trading lower after JP Morg...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
JP Morgan Downgrades Genmab to Neutral
Benzinga Newsdesk
Monday, August 19, 2024
Genmab A/S Announces TEPKINLY Has Received Se...
Benzinga Newsdesk
Friday, August 16, 2024
Genmab Executive Vice President And COO Antho...
Benzinga Newsdesk
Tuesday, August 13, 2024
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
Avi Kapoor
Friday, August 09, 2024
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Thursday, August 08, 2024
Genmab Updates FY24 Revenue Guidance From DKK...
Benzinga Newsdesk
Tuesday, August 06, 2024
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Monday, August 05, 2024
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Vandana Singh
Genmab Takes Over Acasunlimab Development, Bi...
Benzinga Newsdesk
Thursday, August 01, 2024
What 8 Analyst Ratings Have To Say About Genmab
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Thursday, July 18, 2024
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Monday, July 15, 2024
What 8 Analyst Ratings Have To Say About Genmab
Benzinga Insights
RBC Capital Upgrades Genmab to Outperform
Benzinga Newsdesk
Friday, June 28, 2024
Reported Earlier, Genmab's Epcoritamab Receiv...
Benzinga Newsdesk
Thursday, June 27, 2024
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
Vandana Singh
BTIG Maintains Buy on Genmab, Raises Price Ta...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Genmab Announced That The U.S. FDA Approved E...
Benzinga Newsdesk
Thursday, June 20, 2024
10 Analysts Assess Genmab: What You Need To Know
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Genmab,...
Benzinga Newsdesk
Tuesday, June 04, 2024
Truist Securities Maintains Buy on Genmab, Ra...
Benzinga Newsdesk
Monday, June 03, 2024
Genmab's Phase 2 Trial Shows Tisotumab Vedoti...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
